Treatment News : HIV’s Power Harnessed for Good in New Gene Therapies

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 18, 2013

HIV’s Power Harnessed for Good in New Gene Therapies

HIV has a new role in cutting-edge genetic therapies in which the virus is rendered harmless but retains the power to infect cells and introduce genetic code, the Los Angeles Times reports. In December, physicians at the University of Pennsylvania announced they had cured a girl dying of leukemia using a variation of this technique. And now Italian scientists have successfully used deactivated HIV to cure children of two rare, fatal genetic diseases, including three young people with metachromatic leukodystrophy and three others with Wiskott-Aldrich syndrome. Both hereditary conditions are the consequence of genetic mutations that inhibit the body’s capacity to produce certain important enzymes. The investigators published their findings in the journal Science.

The investigators drew bone marrow stem cells from the study participants and then used an HIV-derived lentivirus to replace disease-causing genes in those cells with normal ones. Next they conducted a bone marrow transplant with the modified cells along with chemotherapy to kill off the old immune cells with the faulty genetic code.

Throughout a nearly two-year follow-up period, 45 to 80 percent of the transplanted bone marrow cells produced the necessary proteins in the children with metachromatic leukodystrophy; the number was 25 to 40 percent for those with Wiskott-Aldrich syndrome.

“Three years after the start of the clinical trial, the results obtained from the first six patients are very encouraging: The therapy is not only safe, but also effective and able to change the clinical history of these severe diseases,” Luigi Naldini, MD, PhD, director of San Raffaele Telethon Institute for Gene Therapy (TIGET) in Milan, Italy, and the study’s head researcher, said in a release. “After 15 years of effort and our successes in the laboratory, but frustration as well, it’s really exciting to be able to give a concrete solution to the first patients.”

To read the LA Times story, click here.

To read a release on the study, click here.

Search: HIV, viral vector, genetic therapy, Los Angeles Times, University of Pennsylvania, metachromatic leukodystrophy, Wiskott-Aldrich syndrome, lentivirus, Luigi Naldini.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.